Article · 13 Feb 2026
Review articlePublished 2018
A Budding Cannabis Cottage-Industry has set the stage for an Impending Public Health Crisis
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
There is only one legally-competent authority in the United States (US) that can determine what is and what isn’t medicine – the Food & Drug Administration. In 2018, under US and International statutes, marijuana is not medicine. Individual states have approved the cultivation, sale, and distribution of a Schedule I controlled substance in direct violation of International and U.S. drug control statutes. The current administration of the US allows the daily violation and nullification of 3 International United Nation treaties as well as the US Comprehensive Drug Abuse and Control Act (1970). In a search for nirvana, a growing subculture has emerged that has taken the hallucinogen, Δ9- tetrahydrocannabinol (THC), of the 1960s to “infinity and beyond”. Techniques to “boost” or potentiate the actual THC content of marijuana by agricultural refinement, fertilization, and hybrid cultivation of “home grown” or medical advocate suppliers for the “medicinal marijuana” market has dramatically changed the subjective experience of smoked product. More disturbing is the intentional adulteration of bulk harvested materials (spicing), the development of “kitchen-based” extraction techniques (dabbing), and the processes of dose administrations that have grown almost exponentially over the last decade that sets the stage for a new chimera to drug safety in the US. These cottage industries are poised and waiting for national drug control policies to be further weakened to the point of a public health crisis. While legislators debate the drug control issue, a whole subliminal industry has developed in anticipation of free farming of cannabis, with the intent of delivering hybrid dosing of THC concentrations not believed to be possible just a few years ago.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Pharmaceutical Regulatory Affairs: Open Access.
Article · 11 Feb 2026
EU GMP Annex 1 of 2022: A View in Depth
Article · 11 Feb 2026
Standard Formats Used in Drug Regulatory Submissions and Software Used
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Gauvin DV”
